331 related articles for article (PubMed ID: 15718287)
1. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor.
Zhang Y; Pardridge WM
J Pharmacol Exp Ther; 2005 Jun; 313(3):1075-81. PubMed ID: 15718287
[TBL] [Abstract][Full Text] [Related]
2. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.
Lee HJ; Engelhardt B; Lesley J; Bickel U; Pardridge WM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1048-52. PubMed ID: 10688622
[TBL] [Abstract][Full Text] [Related]
3. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
4. Brain iron homeostasis.
Moos T
Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
7. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies.
Walus LR; Pardridge WM; Starzyk RM; Friden PM
J Pharmacol Exp Ther; 1996 May; 277(2):1067-75. PubMed ID: 8627518
[TBL] [Abstract][Full Text] [Related]
8. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
9. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
10. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
[TBL] [Abstract][Full Text] [Related]
11. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
Deguchi Y; Kurihara A; Pardridge WM
Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
[TBL] [Abstract][Full Text] [Related]
12. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.
Manich G; Cabezón I; del Valle J; Duran-Vilaregut J; Camins A; Pallàs M; Pelegrí C; Vilaplana J
Eur J Pharm Sci; 2013 Jul; 49(4):556-64. PubMed ID: 23748097
[TBL] [Abstract][Full Text] [Related]
13. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
14. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
Kang YS; Pardridge WM
J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841
[TBL] [Abstract][Full Text] [Related]
15. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
Zhou QH; Boado RJ; Pardridge WM
J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody.
Wu D; Pardridge WM
Drug Metab Dispos; 1998 Sep; 26(9):937-9. PubMed ID: 9733674
[TBL] [Abstract][Full Text] [Related]
17. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.
Pardridge WM; Buciak JL; Friden PM
J Pharmacol Exp Ther; 1991 Oct; 259(1):66-70. PubMed ID: 1920136
[TBL] [Abstract][Full Text] [Related]
18. Brain-specific expression of an exogenous gene after i.v. administration.
Shi N; Zhang Y; Zhu C; Boado RJ; Pardridge WM
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12754-9. PubMed ID: 11592987
[TBL] [Abstract][Full Text] [Related]
19. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
20. Widespread expression of an exogenous gene in the eye after intravenous administration.
Zhu C; Zhang Y; Pardridge WM
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3075-80. PubMed ID: 12202532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
